未登录

A

A. Semke

Russian Academy of Sciences

H指数:21

被引数:1,238

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome

IF3.7

2023-03-023

OAAI

Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia

IF3.4

2022-11-259

OAAI

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome

抗精神病药物所致代谢综合征精神分裂症患者的代谢激素

JOURNAL OF PERSONALIZED MEDICINE

IF3

2022-10-054

OAAI

Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome

IF3.7

2022-09-094

OAAI

Immunoglobulins G of Patients with Schizophrenia Protects from Superoxide: Pilot Results

JOURNAL OF PERSONALIZED MEDICINE

IF3

2022-09-013

OAAI

Marker of schizophrenia with enduring negative symptoms

具有持久阴性症状的精神分裂症的标志物

EUROPEAN PSYCHIATRY

IF6.7

2022-09-010

OAAI

Association between catalytic activity of serum antibodies and brain hypomyelination in patients with schizophrenia

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2021-12-010

PRE

GENDER DIFFERENCES IN THE ASSOCIATION OF POLYMORPHIC VARIANTS OF THE 5-HT2C RECEPTOR GENE AND ANTIPSYCHOTIC-INDUCED HYPERPROLACTINEMIA IN PATIENTS WITH SCHIZOPHRENIA

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2021-10-010

PRE

Effects of long-term therapy with quetiapine and olanzapine on parameters of immunity and cytokine levels in patients with schizophrenia

EUROPEAN PSYCHIATRY

IF6.7

2021-08-130

OAAI

Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals

FRONTIERS IN PSYCHIATRY

IF3.2

2021-07-028

OAAI

Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction

TRANSLATIONAL PSYCHIATRY

IF6.2

2021-06-3018

OAAI

Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia

JOURNAL OF PERSONALIZED MEDICINE

IF3

2021-03-0512

OAAI

A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

IF3.9

2021-03-017

OAAI

Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study

IF3.7

2021-01-0517

OAAI

An increase in central nervous system signaling proteins as a criterion for the severity of schizophrenia

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2020-11-010

PREAI

Proteolytic activity of serum collagen-hydrolyzing antibodies in schizophrenia patients

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2020-11-011

PREAI

Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia

IF3.7

2020-10-1421

OAAI

Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome

IF3.3

2020-09-1011

OAAI

Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia

JOURNAL OF IMMUNOLOGY RESEARCH

IF3.6

2020-08-1111

OAAI

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia

FRONTIERS IN MOLECULAR NEUROSCIENCE

IF3.8

2020-04-249

OAAI